W. De Roock
Katholieke Universiteit Leuven
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by W. De Roock.
Annals of Oncology | 2009
Hubert Piessevaux; Marc Buyse; W. De Roock; Hans Prenen; Michael Schlichting; E. Van Cutsem; Sabine Tejpar
BACKGROUND Early radiological tumor shrinkage may be associated with better long-term outcome in chemorefractory metastatic colorectal cancer (cmCRC) treated with cetuximab. We aimed at validating this in a large and independent series. PATIENTS AND METHODS Of the 329 patients, 289 had a measurement both at baseline and week 6. Tumor shrinkage was expressed as a relative decrease compared with baseline and categorized according to a previously reported cut-off value ( approximately 10%) or used as a continuous variable. RESULTS Median time to progression (TTP) was 6.1 [95% confidence interval (CI) 5.1-7.2] versus 1.5 months (95% CI 1.4-1.7) in patients with [99 patients (34.3%)] or without [190 patients (65.7%)] tumor shrinkage, respectively, at week 6 [hazard ratio (HR) 0.23 (95% CI 0.17-0.32)]. The median overall survival (OS) was 13.7 (CI NA) versus 6.9 months (95% CI 6.1-7.7) [HR 0.21 (95% CI 0.14-0.32)], respectively. In a multivariate model, early tumor decrease outperformed skin toxicity as a predictor of long-term outcome. CONCLUSIONS Tumor shrinkage at 6 weeks is a strong predictor of TTP and OS in cmCRC patients treated with cetuximab with or without irinotecan. This suggests early tumor shrinkage is the hallmark of efficacy of cetuximab and reliably identifies the subpopulation that is sensitive to the drug. Early tumor shrinkage can be used as a marker of efficacy in clinical practice, as such or in combination.
Ejc Supplements | 2008
W. De Roock; M. Janssens; Bart Biesmans; Bart Jacobs; J. De Schutter; Yves Humblet; Marc Peeters; E. Van Cutsem; P Marynen; Sabine Tejpar
De Roock, Wendy ; Janssens, Marc ; Biesmans, Bart ; Jacobs, Bart ; De Schutter, Jef ; et. al. DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease.20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics ((Switzerland) Geneva, du 24/10/2008 au 28/10/2008). In: EJC Supplements, Vol. 6, no. 12, p. 33 (2008) http://hdl.handle.net/2078.1/59065 -DOI : 10.1016/ S1359-6349(08)72030-5
Annals of Oncology | 2008
W. De Roock; Hubert Piessevaux; J. De Schutter; M. Janssens; G. De Hertogh; Nicola Personeni; Bart Biesmans; J Van Laethem; Marc Peeters; Yves Humblet; E. Van Cutsem; Sabine Tejpar
Journal of Clinical Oncology | 2008
Sabine Tejpar; M Peeters; Yves Humblet; Jan B. Vermorken; G. De Hertogh; W. De Roock; Johannes Nippgen; A. von Heydebreck; Christopher Stroh; E. Van Cutsem
Journal of Clinical Oncology | 2008
F. Di Fiore; E. Van Cutsem; Pierre Laurent-Puig; S. Siena; Milo Frattini; W. De Roock; Astrid Lièvre; Andrea Sartore-Bianchi; Alberto Bardelli; Sabine Tejpar
Journal of Clinical Oncology | 2009
Diether Lambrechts; W. De Roock; Hans Prenen; J. De Schutter; Bart Jacobs; Bart Biesmans; Bart Claes; G. De Hertogh; E. Van Cutsem; Sabine Tejpar
Ejc Supplements | 2009
Sabine Tejpar; W. De Roock
Annals of Oncology | 2012
Veerle De Vriendt; W. De Roock; A. F. Di Narzo; Sun Tian; Bart Biesmans; Bart Jacobs; J. De Schutter; E Budzinska; Xavier Sagaert; M. Delorenzi; Iris Simon; Sabine Tejpar
Annals of Oncology | 2010
Sabine Tejpar; W. De Roock; Bart Claes; George Fountzilas; Konstantine T. Kalogeras; Kotoula-Dimitriadou; Pierre Laurent-Puig; Frédérique Penault-Llorca; P. Rougier; Bruno Vincenzi; Daniele Santini; Giuseppe Tonini; Federico Cappuzzo; Milo Frattini; F Molinari; Piercarlo Saletti; S. De Dosso; Alberto Bardelli; S. Siena; Andrea Sartore-Bianchi; F DiNicolantonio; Josep Tabernero; Teresa Macarulla; F DiFiore; A Oden-Gangloff; Fortunato Ciardiello; Per Pfeiffer; Camilla Qvortrup; T. Plato Hansen; Eric Van Cutsem
Journal of Clinical Oncology | 2008
Nicola Personeni; Hubert Piessevaux; Steffen Fieuws; F. Di Fiore; W. De Roock; Bart Biesmans; J. De Schutter; E. Van Cutsem; Sabine Tejpar
